Bionomics Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with unmet medical needs. The Company operates in the drug development segment in Australia. The Company is advancing its lead drug candidate, BNC210, which is an oral, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. It also includes a pre-clinical CNS pipeline that has two earlier-stage small molecule discovery programs targeting ion channels and representing opportunities for clinical programs.